Explore

Trendline Trendline
Serif Biomedicines Unveils Promising Data on Modified DNA for Genetic Medicines

Serif Biomedicines Unveils Promising Data on Modified DNA for Genetic Medicines

Serif Biomedicines Unveils Promising Data on Modified DNA for Genetic Medicines
Trendline Trendline
Lantern Pharma to Announce Q1 2026 Financial Results Amid AI-Driven Oncology Developments

Lantern Pharma to Announce Q1 2026 Financial Results Amid AI-Driven Oncology Developments

Lantern Pharma to Announce Q1 2026 Financial Results Amid AI-Driven Oncology Developments
Trendline Trendline
AI and Biotechnology Convergence Drives Personalized Medicine Advancements

AI and Biotechnology Convergence Drives Personalized Medicine Advancements

AI and Biotechnology Convergence Drives Personalized Medicine Advancements
Trendline Trendline
Thryv Therapeutics to Present SGK1 Inhibitor Progress at Major Healthcare Conferences

Thryv Therapeutics to Present SGK1 Inhibitor Progress at Major Healthcare Conferences

Thryv Therapeutics to Present SGK1 Inhibitor Progress at Major Healthcare Conferences
Trendline Trendline
Savara to Participate in H.C. Wainwright Co. BioConnect Investor Conference

Savara to Participate in H.C. Wainwright Co. BioConnect Investor Conference

Savara to Participate in H.C. Wainwright Co. BioConnect Investor Conference
Trendline Trendline
Alto Neuroscience to Present at Major Healthcare Conferences, Highlighting Precision Psychiatry Innovations

Alto Neuroscience to Present at Major Healthcare Conferences, Highlighting Precision Psychiatry Innovations

Alto Neuroscience to Present at Major Healthcare Conferences, Highlighting Precision Psychiatry Innovations
Trendline Trendline
Halia Therapeutics to Present Phase 2 Ofirnoflast Data and Appoints New Chief Medical Officer

Halia Therapeutics to Present Phase 2 Ofirnoflast Data and Appoints New Chief Medical Officer

Halia Therapeutics to Present Phase 2 Ofirnoflast Data and Appoints New Chief Medical Officer
Trendline Trendline
AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials
Trendline Trendline
Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers

Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers

Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers
Trendline Trendline
FORE Biotherapeutics to Engage in Key Investor Conferences, Highlighting Oncology Innovations

FORE Biotherapeutics to Engage in Key Investor Conferences, Highlighting Oncology Innovations

FORE Biotherapeutics to Engage in Key Investor Conferences, Highlighting Oncology Innovations
Trendline Trendline
AN2 Therapeutics Reports Q1 2026 Financial Results and Advances Clinical Programs

AN2 Therapeutics Reports Q1 2026 Financial Results and Advances Clinical Programs

AN2 Therapeutics Reports Q1 2026 Financial Results and Advances Clinical Programs
Trendline Trendline
Actio Biosciences Initiates Trial for KCNT1-Related Epilepsy Treatment

Actio Biosciences Initiates Trial for KCNT1-Related Epilepsy Treatment

Actio Biosciences Initiates Trial for KCNT1-Related Epilepsy Treatment